High Vasopressin, Low Water Intake
Conditions
Keywords
Hydration, Water, Vasopressin, Copeptin, Glucose
Brief summary
This study evaluates increased hydration (1.5 L of water daily during 6 weeks) on top of habitual water intake in the lowering of the vasopressin marker copeptin and in the lowering of plasma glucose concentration in adults with signs of low water intake at recruitment (elevated levels of copeptin, high urine osmolality, low urine volume).
Detailed description
High plasma concentration of vasopressin (i.e. antidiuretic hormone) is a novel and independent risk factor for type 2 diabetes, the metabolic syndrome, cardiovascular disease and premature death. The main physiological role of vasopressin is to maintain constant plasma osmolality. Previous studies in rats and a Mendelian randomization study in humans suggest causality between elevated vasopressin concentration and elevated plasma glucose concentration. As vasopressin can be suppressed by increasing water intake, the investigators hypothesize that water supplementation in individuals with high vasopressin can lower plasma glucose and prevent diabetes. The aim of this pilot study is to test if six weeks of water supplementation of 1.5 Liters of extra water per day in low-drinkers with high copeptin can significantly alter hydration markers in general and reduce plasma copeptin in particular. Furthermore, the investigators also aim at investigating whether this 6-week water intervention can significantly reduce fasting plasma glucose concentration.
Interventions
DIETARY_SUPPLEMENTWater
Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
Sponsors
Lund University
Danone Global Research & Innovation Center
Region Skane
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
All participants of this pilot intervention study had the intervention of 1.5 Liters of increased daily water intake per day during 6 weeks.
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Provision of informed consent * Age 20-75 years * High plasma concentration of copeptin of \>6.1 pmol/L in women and \> 10.7 pmol/L in men * 24-hour urine osmolality \> 600 milliosmol (mosm) /kg water.
Exclusion criteria
* 24-hour urine volume \>1.5 L * Pregnancy or breastfeeding * Plasma sodium \<135 mmol/L * Use of diuretics, lithium or SSRI drugs * Chronic kidney disease (estimated glomerular filtration rate \< 30mL/min) * Heart failure * Inflammatory bowel disease * Type 1 diabetes or type 2 diabetes treated with insulin * Vulnerable subjects (subjects with legal guardian, with loss of personal liberty)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fasting plasma copeptin concentration (pmol/L) | 6 weeks | Change of fasting plasma copeptin between baseline and after 6 weeks of increased water intake. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 24 hour urine osmolality (mosm/kg H2O) | 6 weeks | Change of 24 hour urine osmolality between baseline and after 6 weeks of increased water intake. |
| 24 hour urine volume (L/24h) | 6 weeks | Change of 24 hour urine volume between baseline and after 6 weeks of increased water intake. |
| Drinking water (L/day) | 6 weeks | Change of intake of tap and bottled water between baseline and after 6 weeks of increased water intake. |
| Total water (L/day) | 6 weeks | Change of total water intake between baseline and after 6 weeks of increased water intake. |
| Fasting plasma glucose concentration (mmol/L) | 6 weeks | Change of Fasting plasma glucose concentration between baseline and after 6 weeks of increased water intake. |
Countries
Sweden
Outcome results
None listed